文献速递肝病消化道肿瘤与早癌

美国肝移植候选者中肝细胞癌局部区域治疗的国家趋势与等待名单结局

National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-08-03

该研究基于美国器官获取与移植网络2003至2018年数据,纳入31,609例获批肝细胞癌例外的成人肝移植候选者,分析局部区域治疗的使用趋势及等待名单脱落风险。结果显示至少接受一次局部区域治疗的比例从42.3%升至92.4%,任何类型局部区域治疗均与较低的等待名单脱落风险相关,放射性栓塞或消融作为首次治疗较化疗栓塞进一步降低脱落风险。

要点

  • 肝移植候选者中局部区域治疗使用率从2003年42.3%增至2018年92.4%。
  • 任何类型局部区域治疗均与较低的等待名单脱落风险相关。
  • 放射性栓塞或消融作为首次治疗较化疗栓塞降低等待名单脱落风险。

核心结论

  • 在肝细胞癌肝移植候选者中,局部区域治疗越来越多地用于桥接移植,尤其放射性栓塞使用增加。
  • 桥接局部区域治疗与较低的等待名单脱落风险相关。

研究设计与样本

  • 研究为基于美国器官获取与移植网络数据库的回顾性队列分析,纳入2003至2018年获批肝细胞癌例外的成人肝移植候选者。
  • 共纳入31,609例符合条件患者,24,145例候选者接受了34,610次治疗。
  • 采用多变量竞争风险分析评估局部区域治疗类型与等待名单脱落的关系。

主要发现

  • 至少记录一次局部区域治疗的比例从2003年的42.3%上升至2018年的92.4%。
  • 化疗栓塞仍是最常见类型,其次为热消融;放射性栓塞从2013年的3%增至2018年的19%。
  • 肿瘤负荷超出米兰标准、甲胎蛋白水平较高及肝病代偿更充分的患者接受局部区域治疗的发生率更高。
  • 接受任何类型局部区域治疗与较低的等待名单脱落风险相关,且脱落风险与局部区域治疗次数无显著差异。
  • 在逆概率治疗加权调整分析中,放射性栓塞或消融作为首次局部区域治疗较化疗栓塞与降低的等待名单脱落风险相关。

临床怎么用

  • 对于等待肝移植的肝细胞癌患者,可考虑使用局部区域治疗进行桥接以降低等待名单脱落风险。
  • 放射性栓塞或消融作为首次局部区域治疗可能较化疗栓塞进一步降低脱落风险。
  • 肿瘤负荷较大或肝病代偿更充分的患者更可能接受多次局部区域治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Policy changes in the United States have lengthened overall waiting times for patients with hepatocellular carcinoma (HCC). We investigated temporal trends in utilization of locoregional therapy (LRT) and associated waitlist outcomes among liver transplant (LT) candidates in the United States. METHODS: Data for primary adult LT candidates listed from 2003 to 2018 who received HCC exception were extracted from the Organ Procurement and Transplantation Network database. Explant histology was examined, and multivariable competing risk analysis was used to evaluate the association between LRT type and waitlist dropout. RESULTS: There were 31,609 eligible patients with at least 1 approved HCC exception, and 34,610 treatments among 24,145 LT candidates. The proportion with at least 1 LRT recorded increased from 42.3% in 2003 to 92.4% in 2018. Chemoembolization remains the most frequent type, followed by thermal ablation, with a notable increase in radioembolization from 3% in 2013 to 19% in 2018. An increased incidence of LRT was observed among patients with tumor burden beyond Milan criteria, higher α-fetoprotein level, and more compensated liver disease. Receipt of any type of LRT was associated with a lower risk of waitlist dropout; there was no significant difference by number of LRTs. In inverse probability of treatment weighting-adjusted analysis, radioembolization or ablation as the first LRT was associated with a reduced risk of waitlist dropout compared with chemoembolization. CONCLUSIONS: In a large nationwide cohort of LT candidates with HCC, LRT, and in particular radioembolization, increasingly was used to bridge to LT. Patients with greater tumor burden and those with more compensated liver disease received more treatments while awaiting LT. Bridging LRT was associated with a lower risk of waitlist dropout.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kwong AJ, Ghaziani TT, Yao F, et al. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol. 2021. PMID: 34358718. doi:10.1016/j.cgh.2021.07.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。